SCHEMBL70835

SCHEMBL70835

COc1ccc(C=O)cc1OC1CCCC1

nearest known ligand 0.64

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
TSHR P16473 1/20 0.64
PDE4B Q07343 12/20 0.61
PDE3A Q14432 1/20 0.57
PDE4D Q08499 5/20 0.56
PDE4A P27815 4/20 0.56
PDE4C Q08493 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29808190 1.00 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL7560477 1.00 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL4637156 0.98 ALDH1A1 (0.62) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL6883557 0.98 ALDH1A1 (0.66) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL2840516 0.94 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL22713946 0.94 ALDH1A1 (0.68) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL2847455 0.92 ALDH1A1 (0.62) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL27512098 0.91 PDE4B (0.59) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL8845986 0.90 PDE4B (0.49) ALDH1A1TSHRPDE4BPDE3APDE4D
SCHEMBL5905463 0.89 PDE4B (0.48) ALDH1A1TSHRPDE4BPDE3APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1946665-B Preparation method of 3-cyclopentyloxy-4-methoxybenzaldehyde WYETH CORP 2011-06-15 CN claimed
JP-2007532584-A 2007-11-15 JP claimed
CN-1946665-A Preparation method of 3-cyclopentyloxy-4-methoxybenzaldehyde WYETH CORP (US) 2007-04-11 CN claimed
EP-1751081-A2 METHOD FOR PREPARING 3-CYCLOPENTYLOXY-4-METHOXYBENZALDEHYDE Wyeth (US) 2007-02-14 EP claimed
US-7122705-B2 Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde WYETH (US) 2006-10-17 US claimed
WO-2005100291-A2 METHOD FOR PREPARING 3-CYCLOPENTYLOXY-4-METHOXYBENZALDEHYDE WYETH (US) 2005-10-27 WO claimed
US-20050228199-A1 Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde WYETH (US) 2005-10-13 US claimed
US-5274002-A 1-Oxy- or -thio-2-cycloalkyloxy-4-carboxyalkylene benzene derivatives WARNER-LAMBERT COMPANY (US) 1993-12-28 US claimed
JP-7017952-A None JP disclosed
US-12350283-B2 Methods and compositions for treating motor neuron diseases UNIVERSITAT DE VALENCIA-ESTUDI GENERAL (ES) 2025-07-08 US disclosed
CN-120136683-A Catechol ether compound, pharmaceutical composition and application thereof 中国药科大学 2025-06-13 CN disclosed
US-20240415806-A1 METHODS OF TREATING PRADER-WILLI SYNDROME LEVO THERAPEUTICS, INC. 2024-12-19 US disclosed
CN-113473993-B Methods and compositions for treating motor neuron diseases 巴伦西亚大学 2024-06-04 CN disclosed
US-11957656-B2 Methods of treating Prader-Willi syndrome THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-04-16 US disclosed
CN-1058771-A Method for making of oxime carbamate and oxime carbonate ester and uses thereof AMERICAN HOME PROD (US) 1992-02-19 CN disclosed
EP-0470805-A1 Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents AMERICAN HOME PRODUCTS CORPORATION (US) 1992-02-12 EP disclosed
WO-1992000968-A1 OXAMIDES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-23 WO disclosed
US-4971959-A Trisubstituted phenyl analogs having activity for congestive heart failure WARNER-LAMBERT COMPANY (US) 1990-11-20 US disclosed
US-4308278-A Anorexigenic 4-[(3,4-dialkoxyphenyl)alkyl]-2-imidazolidinone derivatives GYOGYSZERKUTATO INTEZET (HU) 1981-12-29 US disclosed
US-4186129-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, ANTICONVULSANTS SCHERING AKTIENGESELLSCHAFT (DE) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228199-A1 Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde PAH, HPD, ACMSD ALDH1A1 941/4885TSHR 4726/4885PDE4B 2673/4885
US-12350283-B2 Methods and compositions for treating motor neuron diseases SMN1; SMN2, NNMT, PDE4A ALDH1A1 237/4885TSHR 4798/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.